BNET Industries

Threshold Pharmaceuticals Inc.

(THLD) is in the Pharma Industry

Market Cap:$65.7M
Last Fiscal Year Sales:$1.4M
  • Public
  • US
Dow Jones Description

We are a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of solid tumors is characterized by, among other things, hypoxia or lack of oxygen, disordered blood vessel growth, and the upregulation of glucose transport. This hypoxic environment is known to be resistant to standard chemotherapy and radiation. It is thought to be responsible for the poor prognosis of many solid tumors and treating the hypoxic environment is currently believed to be a significant unmet medical need. Our product candidates are designed to selectively target the hypoxic microenvironment of tumors either by selective toxin activation in the case of our hypoxia activated prodrug (HAP) program, including TH-302, or potentially utilizing the consequences of increased uptake of glucose in cancer cells relative to most normal cells. Our product candidates glufosfamide and 2DG share certain structural characteristics with glucose but act instead as chemotherapeutic toxins when taken up by a cell. Our focus is on product candidates for the treatment of patients with cancer. We have three product candidates for which we have exclusive worldwide marketing rights: TH-302, which we discovered, is our lead product candidate for the potential treatment of patients with cancer. ...

Number of Employees 31
Contact Information

1300 Seaport Blvd Ste 500

Redwood City, California 94063

thresholdpharm....

(650) 474-8200

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Threshold Pharmaceuticals 3Q loss widens on costs

    11/06/09 - Financial Announcement - View Story

  • Threshold Pharmaceuticals signs licensing agreement with Eleison

    10/16/09 - Joint Venture / Alliance - View Story

  • Threshold Pharmaceuticals, Inc. THLD Licenses Glufosfamide to Eleison Pharmaceuticals

    10/15/09 - Licensing / Contract - View Story

  • Threshold Pharma's Melanoma Drug Shows Promise In Trial

    10/08/09 - Financial Announcement - View Story

  • Threshold Pharmaceuticals secures $35 million in equity financing

    10/08/09 - New Investment - View Story

  • Lazard Capital Upgrades Threshold Pharmaceuticals THLD to Buy

    8/19/09 - Bond / Stock Rating - View Story

News & Analysis

threshold pharmaceuticals inc. - All News and Analysis

advertisement
     THLD $1.96 +0.18 (9.98% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 212,388
Shares Outstanding 33.56M
Market Cap 65.7M
Year High 3.87
Year Low 0.34
Earnings Per Share -1.44
P/E Ratio -1.36
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement
Click Here